Navigation Links
Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.

OXFORD, Miss., Sept. 8 /PRNewswire-FirstCall/ -- Boveran Diagnostics, Inc. (OTC Bulletin Board: BOVD) ("Boveran") today announced its has executed a Letter of Intent ("LOI") to acquire majority interest in Sophora Diagnostic Lab, Inc., a New York-based cancer pathology lab ("Sophora").

Pursuant to the LOI, Dr. Mikhail Kantius will join Boveran Diagnostics as the Company's Chief Pathologist and Director of Lab operations and Business Development for pathology lab services.

Sophora is Boveran's first planned acquisition and headquarters for its new cancer detection system designs and technologies. Additional acquisitions are planned and will be announced as part of the Boveran's lab network revenue and growth plan.

Boveran will soon publish guidance on its planned acquisitions, complete business plan information, revenue models, and details on its new development initiative for its next generation fully-automated computer imaging cancer detection platform.

About Boveran Diagnostics, Inc.

Boveran Diagnostics, Inc. develops cancer detection technologies and markets this technology to pathology laboratories and other cancer diagnostic laboratories. The Company believes that the application of automated cancer detection technologies will provide physicians and laboratories with the genomic information necessary to determine the presence or absence of cancer by reducing the uncertainty for the pathologist and consumer by decreasing false positive and false negatives resulting from current conventional cancer diagnostic techniques. The Company's website can be found at

SEC Filings and Forward-Looking Statements

Additional information regarding Boveran Diagnostics, Inc, is contained in a Report on Form 8-K and Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2008 and August 14, 2008, respectively, by Z Yachts, Inc.

Certain statements made in this release are forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business of Boveran Diagnostics, Inc. and the industries and markets in which Boveran Diagnostics, Inc. operates. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Boveran Diagnostics, Inc. expressly disclaims any intent or obligation to update these forward-looking statements to conform the statement to actual results or changes in the Company's expectations, except as otherwise specifically stated.

Investor Relations:

Contact: Boveran Diagnostics, Inc.,, 1-954-495-9334

SOURCE Boveran Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
Breaking Biology News(10 mins):